Gyula Ostoros

机构：Országos Korányi Tbc és Pulmonológiai Intézet · ORCID：0000-0001-5339-7257

发表论文 135 篇 · 总被引 15034 次 · h-index 29

代表论文

• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (2019 · The Lancet · 被引 3390)
• Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer (2023 · New England Journal of Medicine · 被引 782)
• Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions (2023 · CA A Cancer Journal for Clinicians · 被引 368)
• Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses (2019 · Journal of Thoracic Oncology · 被引 151)
• SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer (2023 · Annals of Oncology · 被引 102)
• LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2 (2024 · ESMO Open · 被引 76)